Large Population Study Bolsters Aspirin as VTE Prophylaxis of Choice in Joint Arthroplasty
Camrelizumab Plus Rivoceranib Boosts Survival Rates Over Sorafenib in uHCC
MARIPOSA Analysis: Amivantamab Plus Lazertinib Is ‘Important New Standard of Care’ for Certain Patients With NSCLC